HOME ·

IMPACT THERAP-B

IMPACT THERAP-B (07630.HK): Executive director and CEO increases stake with purchase of 100,000 shares, holding rises to approximately 6.564%
Tags：
IMPACT THERAP-B07630.HKShare Increase
2026-09-03
IMPACT THERAP-B (07630.HK): Nominates IMP2794 as preclinical candidate compound, first KAT6A-specific PROTAC from self-owned targeted protein degradation platform
Tags：
IMPACT THERAP-B07630.HKR&D Progress
2026-08-12
IMPACT THERAP-B (07630.HK): H1 Revenue Expected to Surge 276% to 359% with Loss Narrowing 22% to 37%, Driven by Senaparib's NRDL Inclusion
Tags：
IMPACT THERAP-B07630.HKloss narrowed
2026-08-11
IMPACT THERAP-B (07630.HK): Clinical Data of Senaparib, IMP1734 and IMP1707 Accepted for Poster Presentations at ESMO Congress 2026
Tags：
IMPACT THERAP-B07630.HKposter presentation
2026-07-20